Exclusive analysis of biotech, pharma, and the life sciences

In-depth analysis of biotech, pharma, and the life sciences

from some of the nation's most trusted and well-connected reporters in the industry

with STAT+ reporters and leading industry experts in our STAT+ Conversations series

hosted by STAT+, plus early-bird access and discounts to industry events around the country

get delivered to your inbox to brief you on the most important industry news of the day

like our CRISPR Trackr and Drug Pricing Policy Tracker

In-depth analysis of biotech, pharma, and the life sciences

from some of the nation's most trusted and well-connected reporters in the industry

with STAT+ reporters and leading industry experts in our STAT+ Conversations series

hosted by STAT+, plus early-bird access and discounts to industry events around the country

get delivered to your inbox to brief you on the most important industry news of the day

like our CRISPR Trackr and Drug Pricing Policy Tracker

D NA sequencing giant Illumina announced Thursday that it would enter the field of drug discovery, a major shift for a company that, since its founding in 1998, has thrived instead by selling picks and shovels to the prospectors of biotech’s various gold rushes.

The effort will be a partnership with Deerfield Asset Management, an investment firm, which the company said will provide “expertise in early stage drug development,” and will aim to identify proteins that can be targets for new medicines using genetic data and artificial intelligence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

Senior Writer, Medicine, Editorial Director of Events

Matthew covers medical innovation — both its promise and its perils.

This name will appear with your comment

There was an error saving your display name. Please check and try again.

Reporting from the frontiers of health and medicine